• RxStrategies Clinical Insights — October Issue 1

    Welcome to the first October edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Tresiba® (insulin degludec injection) September 25, 2015 — The U.S. Food and Drug Administration approved Tresiba® (insulin degludec injection) and Ryzodeg® 70/30 (insulin degludec/insulin… Read more »

  • RxStrategies Clinical Insights — September 2015 Issue 1

    Welcome to the first September edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Xuriden™ (uridine triacetate) September 4, 2015 — The U.S. Food and Drug Administration approved Xuriden™ (uridine triacetate), the first FDA-approved treatment for patients with… Read more »

  • September 340B Insider

    Welcome to the September edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   RxStrategies’ Perspective: Proposed Mega Reg Guidance As you know, the Health Resources and Services Administration (HRSA) released on August 28, the provisions of the 340B Drug Pricing Program Omnibus Guidance (Proposed Guidance). The Proposed Guidance… Read more »

  • RxStrategies Travels the Country in 2015

    So far this year, the RxStrategies team has traveled from San Francisco to Washington D.C.—with many stops in between—to share the latest developments on the 340B drug discount program. Throughout the rest of the year, we will be attending and presenting at conferences in Florida, Alabama, Alaska, Georgia, California and New Orleans. Aug. 21-25 RxStrategies… Read more »

  • August 340B Insider

    Welcome to the August edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B RECERTIFICATION REMINDER   Recertification Deadline September 9    340B Health sent a reminder to Covered Entities (CEs) regarding the Sept. 9 deadline to recertify information in the 340B program database. It is vital to… Read more »

  • RxStrategies Clinical Insights — August 2015 Issue 1

    Welcome to the August edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Odomzo® (sonidegib) July 24, 2015 — The U.S. Food and Drug Administration approved Odomzo® (sonidegib) to treat patients with locally advanced basal cell carcinoma that… Read more »

  • RxStrategies Clinical Insights — June/July Issue 1

    Welcome to the June/July edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Kengreal™ (cangrelor) June 22, 2015 — The U.S. Food and Drug Administration approved Kengreal™ (cangrelor), an intravenous antiplatelet drug that prevents formation of harmful blood… Read more »

  • June 340B Insider

    Welcome to the June edition of RxStrategies 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.   340B UPDATES   21st Century Cures Act Moves Forward Without 340B Language On May 21, the House Energy and Commerce Committee unanimously approved the 21st Century Cures Act (H.R. 6) without the inclusion of… Read more »